Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide (CABPOSTAAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03764540
Recruitment Status : Recruiting
First Posted : December 5, 2018
Last Update Posted : July 22, 2020
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Centre hospitalier de l'Université de Montréal (CHUM)

Brief Summary:

Prostate cancer (PCa) is the most frequently diagnosed cancer in Canadian men. While the majority of PCa is slow growing and responds well to first line treatment, a proportion of cases (10%) progress to metastatic form resulting in more than 4 000 deaths annually in Canada and 250 000 worldwide. Currently, first line treatment for PCa includes surgery, radiation and androgen deprivation therapy (ADT). A rapid evolution in the understanding of disease biology, combined with approvals of new therapies including immunotherapy, novel chemotherapy, hormonal agents and a bone calcium matrix-targeted radionuclide, along with further drugs in development, have made treatment decisions for metastatic castration-resistant prostate cancer (mCRPC) increasingly complex and challenging.

This is a Phase II Study of Cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). The current study is designed to determine if cabazitaxel will improve progression free survival (PFS) or overall survival (OS).

This study will enroll patients with mCRPC, who have been previously treated and progressed under docetaxel or abiraterone regimen.

Patients must meet the study eligibility criteria and must be competent to give informed consent.


Condition or disease Intervention/treatment Phase
Metastatic Prostate Cancer Drug: Cabazitaxel plus prednisone Drug: Docetaxel plus prednisone Phase 2

Detailed Description:

This is a prospective, multicenter, national, randomized, open label study, comparing the efficacy of cabazitaxel at 25 mg/m² plus prednisone (Arm A) over docetaxel at 75mg/m2 plus prednisone (Arm B) after enzalutamide at 160 mg once daily or abiraterone acetate at 1000 mg once daily plus prednisone in chemotherapy-naïve patients with mCRPC who have progressed on abiraterone acetate or enzalutamide.

Each patient will be treated until disease progression, unacceptable toxicity, or patient's refusal of further study treatment.

All eligible patients will be randomly assigned to either arm A or B in a 1:1 proportion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 214 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Study of Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide Progression
Actual Study Start Date : April 1, 2019
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Steroids

Arm Intervention/treatment
Experimental: Cabazitaxel plus prednisone

Cabazitaxel: Single-dose vial, containing a total of 60 mg of cabazitaxel expressed as anhydrous and solvent-free basis, per 1.5 mL of solution. Cabazitaxel will be administered by IV route Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).

Prednisone will be administered by oral route

Drug: Cabazitaxel plus prednisone

Cabazitaxel 25 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.

A cycle is defined as a 3-weeks period for a maximum of 10 cycles.

Other Name: Experimental

Active Comparator: Docetaxel plus prednisone

Docetaxel is formulated in polysorbate 80 and commercially available as 80 mg/2.0 mL single-dose vials with accompanying diluent (13% ethanol in water for injection) for IV use.

Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).

Prednisone will be administered by oral route

Drug: Docetaxel plus prednisone

Docetaxel 75 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.

A cycle is defined as a 3-weeks period for a maximum of 10 cycles.

Other Name: Active Comparator




Primary Outcome Measures :
  1. PSA response rate at 6 and 12 months [ Time Frame: through study completion, an average of 1 year ]
    Change from baseline PSA level of at least 50%, PSA partial response is defined as a ≥ 50% decline in PSA from cycle 1 day 1 (baseline) PSA value. This PSA change must be confirmed as sustained by a second PSA value obtained ≥ 3 weeks later.


Secondary Outcome Measures :
  1. Radiological progression-free survival (rPFS) [ Time Frame: through study completion, an average of 1 year ]
    Time interval between the date of randomization and the date of the first documentation of any of the following event. Radiological tumor progression by RECIST 1.1 and PCWG2,

  2. Overall Survival [ Time Frame: through study completion, an average of 1 year ]
    Time interval from the date of randomization to the date of death due to any cause

  3. Time to PSA progression (TTPP) [ Time Frame: through study completion, an average of 1 year ]
    Time interval between the date of randomization and the date of first documented PSA progression.

  4. Tumor response [ Time Frame: through study completion, an average of 1 year ]
    Measurable by RECIST 1.1

  5. Duration of tumor response [ Time Frame: hrough study completion, an average of 1 year ]
    Time between the first evaluation at which the tumor response criteria are met and the first documentation of tumor progression.

  6. Pain response: BPI-SF pain intensity item scores [ Time Frame: through study completion, an average of 1 year ]
    Decrease by <30% from baseline in the average of BPI-SF pain intensity item scores (items 3, 4, 5, and 6) observed at 2 consecutive evaluations ≥3 weeks apart without increase in analgesic usage score.

  7. Time to Pain progression [ Time Frame: through study completion, an average of 1 year ]
    Time interval between the date of randomization and the date of the first documented pain progression



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of histologically or cytologically confirmed prostate adenocarcinoma.
  • Metastatic disease.
  • Progressive disease (PD) while receiving AR targeted therapy with abiraterone acetate or enzalutamide by at least one of the following:
  • Progression in measurable disease (RECIST 1.1 criteria). Patient with measurable disease must have at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be at least 10 mm when measured by computed tomography (CT) [CT scan thickness no greater than 5 mm] or magnetic resonance imaging (MRI). Lymph nodes should be ≥ 15 mm in short axis. As defined by PCWG2, if lymph node metastasis is the only evidence of metastasis, it must be ≥ 20 mm in diameter when measured by spiral CT or MRI. Previously irradiated lesions, primary prostate lesion and bone lesions will be considered non-measurable disease, and/or
  • Appearance of 2 or more new bone lesions. They must be confirmed by other imaging modalities (CT; MRI) if ambiguous results (PCWG2), and/or
  • Rising PSA defined (PCWG2) as at least two consecutive rises in PSA to be documented over a reference value (measure 1) taken at least one week apart. The first rising PSA (measure 2) should be taken at least 7 days after the reference value. A third confirmatory PSA measure is required (2nd beyond the reference level) to be greater than the second measure and it must be obtained at least 7 days after the 2nd measure. If this is not the case, a fourth PSA measure is required to be taken and be greater than the 2nd measure. The third (or the fourth) confirmatory PSA should be taken within 4 weeks prior to randomization.
  • A PSA value of at least 2 ng/mL is required at study entry.
  • Effective castration (serum testosterone levels ≤0.5 ng/mL).
  • Prior AR targeted therapy (abiraterone acetate or enzalutamide) must be stopped at least 2 weeks before study treatment.
  • Signed written informed consent.

Exclusion Criteria:

Related to methodology:

  • Prior chemotherapy for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed >3 years ago. Prior treatment with sipuleucel T immunotherapy is allowed at the condition patient did not received prior chemotherapy. No further anti-cancer therapy after the previous AR targeted therapy and before inclusion.
  • Less than 28 days elapsed from prior treatment with radiotherapy or surgery to the time of randomization.
  • Prior isotope therapy, whole bony pelvic radiotherapy, or radiotherapy to >30% of bone marrow.
  • Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from any prior anticancer therapy of grade >1(National Cancer Institute Common Terminology Criteria [NCI CTCAE] v4.0) at the time of randomization.
  • Less than 18 years (or country's legal age of majority if the legal age is >18 years).
  • Eastern Cooperative Oncology Group (ECOG) performance status >1.
  • History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease.
  • Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which treatment has been completed ≥5 years ago and from which the patient has been disease-free for ≥5 years.
  • Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.
  • Any of the following within 3 months prior to randomization: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.
  • Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease requiring antiretroviral treatment.
  • Any severe acute or chronic medical condition which could impair the ability of the patient to participate to the study or interfere with interpretation of study results, or patient unable to comply with the study procedures.
  • Patients with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period and up to 6 months after the last administered dose. The definition of "effective method of contraception" will be based on the investigator's judgment.

Related to study treatment

  • Known allergies, hypersensitivity or intolerance to prednisone. History of hypersensitivity to docetaxel or polysorbate 80.
  • Known history of mineralocorticoid excess or deficiency.
  • Unable to swallow a whole tablet or capsule
  • Inadequate organ and bone marrow function as evidenced by:

    1. Hemoglobin <10.0 g/dL
    2. Absolute neutrophil count <1.5 x 109/L
    3. Platelet count <100 x 109/L
    4. AST/SGOT and/or ALT/SGPT >1.5 x ULN;
    5. Total bilirubin >1.0 x ULN
    6. Potassium <3.5 mmol/L
    7. Serum albumin <3.0 g/dL
    8. Child-Pugh Class B and C
    9. Serum Creatinine ≤ 1.5 x ULN,
  • Contraindications to the use of corticosteroid treatment.
  • Symptomatic peripheral neuropathy grade >2 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v.4.0).
  • Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 12 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or cardiac left ventricular ejection fraction (LVEF) measurement of <50% at baseline.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03764540


Contacts
Layout table for location contacts
Contact: Amal Nadiri, PhD 514 890-8000 ext 26074 amal.nadiri.chum@ssss.gouv.qc.ca

Locations
Layout table for location information
Canada, Quebec
Centre Hospitalier de l'Université de Montréal Recruiting
Montréal, Quebec, Canada, H2X 3E4
Contact: fred Saad, MD    5148908000    fredsaad@videotron.ca   
Contact: Amal Nadiri, Ph,D    514890800026074    amal.nadiri.chum@ssss.gouv.qc.ca   
Sponsors and Collaborators
Centre hospitalier de l'Université de Montréal (CHUM)
Genzyme, a Sanofi Company
Layout table for additonal information
Responsible Party: Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov Identifier: NCT03764540    
Other Study ID Numbers: MP-02-2018-7545
First Posted: December 5, 2018    Key Record Dates
Last Update Posted: July 22, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Prednisone
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal